Literature DB >> 22209835

Overexpression of hepatitis B x-interacting protein in HepG2 cells enhances tumor-induced angiogenesis.

Fengze Wang1, Hongrong Fei, Bing Qi, Shutong Yao, Zhengyao Chang.   

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy and a leading cause of cancer death worldwide. Hepatitis B x-interacting protein (HBXIP), a cofactor of survivin, was originally identified by binding with the C-terminus of the HBx and negatively regulated the activity of HBx. In this study, the effect of HBXIP on the hepatoma cells-induced angiogenesis was investigated. Proliferation and migration of human umbilical vein endothelial cells (HUVECs) were detected by MTT and transwell assay, respectively. Tube formation and chick chorioallantoic membrane model were used to observe the angiogenesis. Vascular endothelial growth factor activity was assayed using ELISA kits. Western blotting was performed to examine the protein expression. Our results indicated that overexpression of HBXIP increased HepG2 cell-induced endothelial cells migration, proliferation, and angiogenesis, which may be related to increasing phosphorylation of endothelial NO synthase in HUVECs. These results suggest that HBXIP may play an important role in tumorigenesis by enhancing angiogenesis in HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209835     DOI: 10.1007/s11010-011-1215-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

Review 1.  Angiogenesis in chronic liver disease and its complications.

Authors:  Stephanie Coulon; Femke Heindryckx; Anja Geerts; Christophe Van Steenkiste; Isabelle Colle; Hans Van Vlierberghe
Journal:  Liver Int       Date:  2010-11-15       Impact factor: 5.828

Review 2.  Hepatitis B virus-induced oncogenesis.

Authors:  Joachim Lupberger; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling.

Authors:  Jun Qin; Xinpu Chen; Li-Yuan Yu-Lee; Ming-Jer Tsai; Sophia Y Tsai
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

Review 4.  Endothelial cell migration during angiogenesis.

Authors:  Laurent Lamalice; Fabrice Le Boeuf; Jacques Huot
Journal:  Circ Res       Date:  2007-03-30       Impact factor: 17.367

Review 5.  Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis.

Authors:  Shirine Benhenda; Delphine Cougot; Marie-Annick Buendia; Christine Neuveut
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

6.  Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication.

Authors:  M Melegari; P P Scaglioni; J R Wands
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling.

Authors:  R D Rudic; E G Shesely; N Maeda; O Smithies; S S Segal; W C Sessa
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

8.  Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 to promote endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells.

Authors:  Zeinab Daher; Pierre-Luc Boulay; Fanny Desjardins; Jean-Philippe Gratton; Audrey Claing
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

Review 9.  Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

Authors:  Gilberto de Castro Junior; Fabio Puglisi; Evandro de Azambuja; Nagi S El Saghir; Ahmad Awada
Journal:  Crit Rev Oncol Hematol       Date:  2006-04-04       Impact factor: 6.312

10.  Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase.

Authors:  Eva Gonzalez; Ruqin Kou; Alison J Lin; David E Golan; Thomas Michel
Journal:  J Biol Chem       Date:  2002-08-19       Impact factor: 5.157

View more
  7 in total

1.  HBXIP, a binding protein of HBx, regulates maintenance of the G2/M phase checkpoint induced by DNA damage and enhances sensitivity to doxorubicin-induced cytotoxicity.

Authors:  Hongrong Fei; Yunsheng Zhou; Ruotong Li; Mingfeng Yang; Jian Ma; Fengze Wang
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

2.  Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Honggang Xia; Lan Ma; Jing Li; Hongyu Bai; Dongbin Wang
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

3.  Upregulating the Expression of Survivin-HBXIP Complex Contributes to the Protective Role of IMM-H004 in Transient Global Cerebral Ischemia/Reperfusion.

Authors:  Shi-Feng Chu; Zhao Zhang; Wei Zhang; Mei-Jin Zhang; Yan Gao; Ning Han; Wei Zuo; Hui-Yong Huang; Nai-Hong Chen
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

4.  HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.

Authors:  Yixuan Wang; Jie Sun; Nan Li; Shuanlong Che; Tiefeng Jin; Shuangping Liu; Zhenhua Lin
Journal:  J Ovarian Res       Date:  2017-04-07       Impact factor: 4.234

5.  HBXIP Regulates Gastric Cancer Glucose Metabolism and Malignancy Through PI3K/AKT and p53 Signaling.

Authors:  Lei Qiu; Feng Lu; Lili Zhang; Gang Wang; Rui Geng; Yongchang Miao
Journal:  Onco Targets Ther       Date:  2020-04-21       Impact factor: 4.147

6.  Oncoprotein LAMTOR5 Activates GLUT1 Via Upregulating NF-κB in Liver Cancer.

Authors:  Jing Zhou; Yajun Li; Danhua Li; Zhi Liu; Jie Zhang
Journal:  Open Med (Wars)       Date:  2019-02-26

7.  Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth.

Authors:  Yang Jiang; Dan Wang; Hui Ren; Ying Shi; Yufei Gao
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.